Connect with us

Technology

Alys Pharmaceuticals launches with $100M financing from Medicxi to advance Immuno-Dermatology focused pipeline

Published

on

Co-founded by world leading dermatology experts and Medicxi Merger of six asset-centric companies to form a new R&D-centric multi-platform pipeline in immuno-dermatology to harness cutting edge-science and technologiesVision to transform the treatment paradigm for several dermatology indications of significant prevalence and major unmet need

BOSTON and GENEVA, Switzerland, Feb. 12, 2024 /PRNewswire/ — Alys Pharmaceuticals, Inc. (“Alys”), an immuno-dermatology focused company, launches today with an R&D pipeline enabled by multiple platform technologies and a $100 million financing by Medicxi. Originating from the aggregation of six asset-centric Medicxi companies, Alys boasts a robust pipeline of innovative programs and platforms targeting multiple dermatological indications.

Co-founded by Medicxi and several world leading dermatology and scientific experts, including John Harris (UMass Chan Medical School), Brian Kim (Icahn School of Medicine at Mount Sinai), Lars French (LMU, Munich), Nobel Prize winner Craig Mello (UMass Chan Medical School), Eric Deutsch (Gustave Roussy) and Mark Prausnitz (Georgia Institute of Technology), Alys aspires to redefine the landscape of dermatological treatments. The Company is run by co-founder and COO Thibaud Portal (formerly Galderma’s Global Head of Prescription Medicines) and Medicxi’s Francesco De Rubertis serves as Chairman of the Board.

Alys believes that emerging indications such as atopic dermatitis, vitiligo, alopecia areata and chronic spontaneous urticaria, will see the next breakthroughs in dermatological advancements. The pipeline also includes programs focused on underserved indications such as mastocytosis, cutaneous T-cell lymphoma or prevention of skin side effects of oncology therapies.

Alys is working with leading institutions such as Institut Gustave Roussy, UMass Chan Medical School, Icahn School of Medicine at Mount Sinai, Georgia Institute of Technology and Empa, the Swiss Federal Laboratories for Materials Science & Technology, demonstrating its commitment to collaborative research and development.

Alys combines the assets and platforms of Aldena Therapeutics, Graegis Pharmaceuticals, Granular Therapeutics, Klirna Biotech, Nira Biosciences and Vimela Therapeutics. With more than a dozen active programs, Alys anticipates further organic pipeline growth from its cutting-edge platforms, covering inflammatory diseases, autoimmune diseases, dermatology supportive care for cancer patients and rare dermatoses. Over the next three years, the company aims to deliver between seven to ten clinical Proof-of-Concept (POC) readouts, and potentially at least one program to advance to registrational studies.

Francesco De Rubertis, Chairman of Alys Pharmaceuticals and Partner at Medicxi commented: “We believe that bringing together several asset-centric companies with a phenomenal team will power up Alys to transform innovation in immuno-dermatology. Alys manages a broad pipeline of assets with diverse risk profiles and will hugely benefit from this change of scale and facilitated access to capital.”

Professor John Harris, Chief Innovation Officer of Alys Pharmaceuticals and Chair of Dermatology at UMass Chan Medical School, added: “It is uniquely exciting to oversee such a rich and diverse pipeline, bringing forward modalities that will break new ground in dermatology, including peptides, sophisticated antibodies, or vectorized siRNA.”

Professor Brian Kim, Vice Chair of Research in the Department of Dermatology at the Icahn School of Medicine at Mount Sinai, added: “With its diverse pipeline, Alys’ commitment to advancing the frontiers of immuno-dermatology has the potential to bring transformative solutions to patients worldwide.”

About Alys Pharmaceuticals

Alys Pharmaceuticals, Inc. (“Alys”) is a Boston and Geneva-based cutting edge pure-play immuno-dermatology company. Alys is backed by international investment firm Medicxi with $100M financing. Alys has a world class leadership team that brings together experts across dermatology and advanced scientific fields, including co-founders Craig Mello (UMass Chan Medical School), John Harris (UMass Chan Medical School), Brian Kim (Icahn School of Medicine at Mount Sinai), Lars French (LMU, Munich), Eric Deutsch (Gustave Roussy) and Mark Prausnitz (Georgia Institute of Technology). Alys is led by dermatology specialist, co-founder and COO Thibaud Portal

It was formed from the aggregation of 6 asset-centric Medicxi companies – Aldena Therapeutics, Graegis Pharmaceuticals, Granular Therapeutics, Klirna Biotech, Nira Biosciences and Vimela Therapeutics. Its pipeline boasts 14 active programs, targeting multiple dermatological indications, including atopic dermatitis, vitiligo, psoriasis and mastocytosis. For further information, please visit www.alyspharma.com.  

About Medicxi

Medicxi is a healthcare-focused investment firm with the mission to create and invest in companies across the full drug development continuum. Leveraging deep expertise in drug development and company creation spanning over two decades, Medicxi invests in early and late-stage therapeutics with a product vision that can fulfill a clear unmet medical need. For more information, please visit: www.medicxi.com.

COI Statement

Mount Sinai and Brian Kim, UMass Chan Medical School, Craig Mello and John Harris, Georgia Institute of Technology and Mark Prausnitz, Gustave Roussy and Eric Deutsch, Lars French have financial interests in Alys.

 

View original content:https://www.prnewswire.co.uk/news-releases/alys-pharmaceuticals-launches-with-100m-financing-from-medicxi-to-advance-immuno-dermatology-focused-pipeline-302059125.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Verndale Welcomes Max Fresen as Chief Experience Officer

Published

on

By

New CXO Brings Over Two Decades of Experience in Advertising and Marketing to Lead the Agency’s Experience Design Team

BOSTON, March 5, 2024 /PRNewswire/ — Verndale, a digital experience agency headquartered in Boston, MA, announced the appointment of Max Fresen as their Chief Experience Officer (CXO). Max joins Verndale from BRANDtho, where he successfully led as CXO, bringing with him over two decades of invaluable experience in the advertising and marketing industry.

Following 2023 investments in the strategy team, Verndale welcomes a new CXO to steward innovation in experience design.

As CXO at Verndale, Max will play a pivotal role in charting the agency’s future. He’ll lead the experience design team and drive initiatives that align with the organization’s strategic goals.

Chris Pisapia, CEO of Verndale, shares, “As we steer Verndale through our transformative growth as a company, our focus on delivering business value remains. Balancing technical expertise with strategic creativity is key. Following our investments in the agency’s strategy team in 2023, we’re thrilled to announce Max Fresen’s hire to steward innovation in experience design. This move expands our creative services and reflects our commitment to redefining digital experiences and propelling clients’ initiatives forward.”

Max’s recruitment reinforces the agency’s commitment to excellence and innovation. In his role as the head of experience design, Max will be responsible for delivering engaging and impactful experiences across all channels and platforms, contributing to Verndale’s evolution as a strategic partner to its clients.

“I’m thrilled to join Verndale at this pivotal moment in the evolution of communication arts. In an era where generative technologies have made the once impossible commonplace, capturing customers’ attention and building a brand has become more challenging than ever,” comments Max. “Navigating the intersection of art and science is now essential for a company’s success. With Verndale’s decades of experience crafting tech-enabled experiences at an enterprise scale, we’re uniquely positioned to be the ideal partner for this transformative journey. I’m excited to contribute to Verndale’s mission and drive impactful outcomes for our clients and their customers.”

Max’s extensive experience and leadership at previous agencies prime him to lead and grow the Experience Design team and drive outcomes for our clients. His passion for pushing the boundaries of technology and psychology and his commitment to making the world a better place through design and innovation make him a valuable addition to the Verndale team. 

About Verndale

Verndale is a digital agency that designs, develops, and delivers high-performing websites and ecommerce experiences. The agency guides clients in creating more human experiences in a digital world and is committed to pushing boundaries, achieving growth objectives, and optimizing digital experiences for its clients and their customers. Verndale offers digital strategy, experience design, digital marketing, customer relationship management (CRM), and sales quoting solutions. The agency leverages best-in-class technologies to deliver clients custom solutions that stand above the rest.

As a recognized Optimizely Premium partner, Verndale has earned seven MVP awards, holds 60 certifications, and boasts 30 global accreditations. In 2023 and 2021, the agency was honored with the Optimizely Partner of the Year award. Verndale is also North America’s leading Sitecore Enterprise Solution provider and Platinum partner. With nine MVPs and 25 certified developers, Verndale’s specializations include Experience Platform, XM Cloud, OrderCloud, CDP & Personalization, and Content Hub. 

For more information about Verndale’s innovative solutions and industry expertise, visit verndale.com. Get in touch with us at hello@verndale.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/verndale-welcomes-max-fresen-as-chief-experience-officer-302078945.html

SOURCE Verndale Corporation

Continue Reading

Technology

EMA Research Webinar to Explore How Enterprises Can Be More Successful with Their Network Automation Initiatives

Published

on

By

According to new research from EMA, only 18% of network automation initiatives are a complete success

LAFAYETTE, Colo., March 5, 2024 /PRNewswire-PRWeb/ — Enterprise Management Associates (EMA™), a leading IT and data management analyst research and consulting firm, today announced it will host a research webinar titled “Enterprise Network Automation: Emerging from the Dark Ages and Reaching Toward NetDevOps,” based on recent research by Shamus McGillicuddy, EMA’s vice president of research covering network management. The research explores the challenges and opportunities of network automation for enterprise IT organizations.

Network automation continues to be a science project for too many companies. With this research, I tried to identify a path forward for IT decision-makers.

According to EMA’s new research, only 18% of network automation initiatives are a complete success. This indicates that network automation remains a significant challenge for many organizations. The webinar will provide insights and guidance to help organizations improve the success of their network automation initiatives.

During this webinar, McGillicuddy will share highlights from this new research, including:

Why nine out of ten IT organizations rely on a mix of vendor solutions and do-it-yourself network automation toolsHow network teams establish an authoritative network source of truth to drive effective network automationHow network teams validate network changes and monitor network complianceWhat pitfalls organizations should look out for on their network automation journey

“The IT industry has been attacking the problem of network automation for decades, and we still cannot get it right,” McGillicuddy said. “There are countless reasons for this ongoing struggle, including complexity, data quality and authority problems, and budget issues. As a result, network automation continues to be a science project for too many companies. With this research, I tried to identify a path forward for IT decision-makers.”

This independent research is sponsored by EfficientIP, IPFabric, NetBox Labs, NetBrain.

The webinar will take place on Tuesday, March 12 at 2:00 p.m. Eastern. Registration is available at: https://info.enterprisemanagement.com/enterprise-network-automation-webinar-pr

About EMA
Founded in 1996, EMA is a leading IT analyst research firm that provides deep insight across the full spectrum of IT and data management technologies. EMA analysts leverage a unique combination of practical experience, insight into industry best practices, and in-depth knowledge of current and planned vendor solutions to help their clients achieve their goals. Learn more about EMA research, analysis, and consulting services for enterprise line of business users, IT professionals, and IT vendors at https://www.enterprisemanagement.com

Media Contact

Raleigh Gould, Enterprise Management Associates, 303-543-9500, rgould@emausa.comhttps://www.enterprisemanagement.com 

Twitter

View original content to download multimedia:https://www.prweb.com/releases/ema-research-webinar-to-explore-how-enterprises-can-be-more-successful-with-their-network-automation-initiatives-302079653.html

SOURCE Enterprise Management Associates

Continue Reading

Technology

Pioneer in Cyber Insurance in Brazil Receives $1.5 Million Funding

Published

on

By

Bluecyber, which offers digital protection insurance to SMEs and families, will expand its operations in Latin America

SÃO PAULO, March 5, 2024 /PRNewswire/ — Bluecyber.insure, a pioneering insurtech in cyber insurance in Brazil, has received a $1.5 million investment from VCs Invisto.com.vc and Bossa Invest, as well as strategic investors from the insurance market. “This investment reflects the investors’ confidence in Bluecyber’s mission to simplify and expand insurance coverage for digital life protection of SMEs and families throughout Latin America, an underserved market with an estimated gross written premium (GWP) of USD 17.3 billion,” says Eduardo Rocha, CEO of Bluecyber.

The investment has already enabled the acquisition of Ismac.io, which developed an innovative Managed Detection and Response (MDR) platform. “This solution allows Bluecyber to continuously monitor its insured portfolio, detecting and responding to security incidents swiftly and efficiently, minimizing the impact of attacks, and delivering more value to the insured, as well as reducing the frequency and severity of claims,” explains Daniel Arruda, Ismac’s founder, who will take over the management of risk and compliance at Bluecyber.

In addition to financial compensation for claims such as data breaches, fines related to local General Data Protection Regulations (GDPR), legal fees, and digital identity theft, the monthly cyber protection insurance subscription offers a help desk for everyday technological issues, antivirus, vulnerability monitoring, risk management, and incident response.

“We are confident that this new phase will be a watershed in the cyber insurance industry, offering innovative and comprehensive solutions,” says Bluecyber’s co-founder Claudio Macedo.

About Bluecyber

Founded in 2021, Bluecyber is a Managing General Agent (MGA) specializing in cyber insurance. It develops products tailored to the needs centered around customer-centricity, structures underwriting capacity with reinsurers and insurers, and cultivates innovative distribution channels. The B2B product sales are conducted entirely digitally through non-traditional channels, including internet providers, software and hardware manufacturers, as well as insurance brokers. Bluecyber aims to conclude 2024 with 10,000 subscribers, striving to simplify cyber protection. Seguros Sura, one of the largest insurance groups in Latin America, serves over 20 million insureds across seven countries and is the issuer of the policies, complying with all regulatory requirements.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/pioneer-in-cyber-insurance-in-brazil-receives-1-5-million-funding-302078880.html

SOURCE Bluecyber

Continue Reading

Trending